Research programme: cancer therapy - Actelion/Johnson & Johnson
Alternative Names: Cancer therapy research programme - Actelion/Johnson & JohnsonLatest Information Update: 27 Jun 2017
Price :
$50 *
At a glance
- Originator Actelion Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
- Developer Actelion Pharmaceuticals
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 12 Jun 2003 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Cancer in Switzerland (unspecified route)